Changes of Plasma Antithrombin Levels in Patients with Hematological Malignancy

LI Ping,ZHOU Rong-fu,XU Jing-yan,CHEN Bing,YANG Yong-gong,ZHANG Qi-guo,SHAO Xiao-yan,GUAN Chao-yang,XU Yong
DOI: https://doi.org/10.3969/j.issn.1009-6213.2010.02.010
2010-01-01
Abstract:Objective To assess the clinical value of antithrombin(AT)for hematological malignancy patients.Methods 195 hematological malignancy patients were divided into newly-diagnosed group,complete remission(CR)group,partial remission(PR)group and progression of disease(PD)group.Clinical data of AT were analyzed retrospectivly for these groups and normal control group.Levels of AT,β2-microglobulin(β2-MG)and lactate dehydrogenase(LDH)were analyzed for multiple myeloma patients.Results The plasma AT activity of of newly-diagnosed group,CR,PR and PD group were lower than control group(P﹤0.01).Compared with CR group,AT of newly-diagnosed group,PR and PD group were decreased(P﹤0.01).For multiple myeloma patients,AT of PD,PR group become lower than CR group(P﹤0.05),but β2-MG of these groups were higher than CR group(P﹤0.05).There was negative correlation between AT and β2-MG(P﹤0.05).Conclusions The determination of levels of AT in patients with hematological malignancy might be important for the evaluation of the effect of treatment and prognosis.
What problem does this paper attempt to address?